Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02139046 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,790
- Enrollment target
NCT02139046 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 1,790 participants.
The verdict
NCT02139046, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,790 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80 mg IR, respectively, in participants with gout.
Interventions
- DRUG Colchicine
- DRUG Naproxen
- DRUG Febuxostat placebo
- DRUG Febuxostat IR
- DRUG Febuxostat XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,790 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02139046
The ClinicalTrials.gov registry entry for NCT02139046 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,790 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Colchicine is the first listed.
NCT02139046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02139046 about?
NCT02139046 is a clinical study titled "Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout". The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg extended release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release (IR) and 80 mg IR, respectively, in participants with gout.
What is the current status of trial NCT02139046?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,790 participants. The study started on 2014-04. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02139046?
The interventions under investigation include: Colchicine (DRUG), Naproxen (DRUG), Febuxostat placebo (DRUG), Febuxostat IR (DRUG), Febuxostat XR (DRUG).
Who is sponsoring clinical trial NCT02139046?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.